{"version":"1.0","provider_name":"\u541b\u5b9e\u751f\u7269","provider_url":"https:\/\/www.junshipharma.com\/en\/","title":"Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor) - \u541b\u5b9e\u751f\u7269","type":"rich","width":600,"height":338,"html":"<blockquote class=\"wp-embedded-content\" data-secret=\"kjzXqnwuY0\"><a href=\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9js110%ef%bc%88xpo1%e6%8a%91%e5%88%b6%e5%89%82%ef%bc%89%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e7%be%8e%e5%9b%bdfda%e6%89%b9-2\/\">Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)<\/a><\/blockquote><iframe sandbox=\"allow-scripts\" security=\"restricted\" src=\"https:\/\/www.junshipharma.com\/en\/%e5%90%9b%e5%ae%9e%e7%94%9f%e7%89%a9js110%ef%bc%88xpo1%e6%8a%91%e5%88%b6%e5%89%82%ef%bc%89%e4%b8%b4%e5%ba%8a%e8%af%95%e9%aa%8c%e7%94%b3%e8%af%b7%e8%8e%b7%e5%be%97%e7%be%8e%e5%9b%bdfda%e6%89%b9-2\/embed\/#?secret=kjzXqnwuY0\" width=\"600\" height=\"338\" title=\"&#8220;Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)&#8221; &#8212; \u541b\u5b9e\u751f\u7269\" data-secret=\"kjzXqnwuY0\" frameborder=\"0\" marginwidth=\"0\" marginheight=\"0\" scrolling=\"no\" class=\"wp-embedded-content\"><\/iframe><script type=\"text\/javascript\">\n\/* <![CDATA[ *\/\n\/*! This file is auto-generated *\/\n!function(d,l){\"use strict\";l.querySelector&&d.addEventListener&&\"undefined\"!=typeof URL&&(d.wp=d.wp||{},d.wp.receiveEmbedMessage||(d.wp.receiveEmbedMessage=function(e){var t=e.data;if((t||t.secret||t.message||t.value)&&!\/[^a-zA-Z0-9]\/.test(t.secret)){for(var s,r,n,a=l.querySelectorAll('iframe[data-secret=\"'+t.secret+'\"]'),o=l.querySelectorAll('blockquote[data-secret=\"'+t.secret+'\"]'),c=new RegExp(\"^https?:$\",\"i\"),i=0;i<o.length;i++)o[i].style.display=\"none\";for(i=0;i<a.length;i++)s=a[i],e.source===s.contentWindow&&(s.removeAttribute(\"style\"),\"height\"===t.message?(1e3<(r=parseInt(t.value,10))?r=1e3:~~r<200&&(r=200),s.height=r):\"link\"===t.message&&(r=new URL(s.getAttribute(\"src\")),n=new URL(t.value),c.test(n.protocol))&&n.host===r.host&&l.activeElement===s&&(d.top.location.href=t.value))}},d.addEventListener(\"message\",d.wp.receiveEmbedMessage,!1),l.addEventListener(\"DOMContentLoaded\",function(){for(var e,t,s=l.querySelectorAll(\"iframe.wp-embedded-content\"),r=0;r<s.length;r++)(t=(e=s[r]).getAttribute(\"data-secret\"))||(t=Math.random().toString(36).substring(2,12),e.src+=\"#?secret=\"+t,e.setAttribute(\"data-secret\",t)),e.contentWindow.postMessage({message:\"ready\",secret:t},\"*\")},!1)))}(window,document);\n\/* ]]> *\/\n<\/script>\n","thumbnail_url":"https:\/\/www.junshipharma.com\/wp-content\/uploads\/2022\/12\/\u65b0\u836f\u8fdb\u5c55.png","thumbnail_width":814,"thumbnail_height":611,"description":"SHANGHAI, China, August 25, 2022 (GLOBE NEWSWIRE) \u2013 Shanghai Junshi Biosciences Co., Ltd (\u201cJunshi Biosciences\u201d, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies, announced today that Suzhou Junjing Biomedical Technology Co., Ltd., a company jointly invested by Junshi Biosciences and Wigen Biomedicine Technology (Shanghai) Co., Ltd., has received a notice from the U.S. Food and Drug Administration (the \u201cFDA\u201d) concerning the approval of the investigational new drug (\u201cIND\u201d) application for XPO1 inhibitor WJ01024 tablets (product code: \u201cJS110\u201d) by the FDA. So far, 6 innovative drugs in Junshi Biosciences\u2019 pipeline have obtained IN"}